Platelet‐derived growth factor D: A new player in the complex cross‐talk between cholangiocarcinoma cells and cancer‐associated fibroblasts
Carmen Berasain, Matias A. Ávila – 20 May 2013
Does mild resistance training resemble a similar stimulus compared to aerobic training?
Dominik Pesta, Martin Burtscher – 20 May 2013
Cognitive improvement after HCV eradication: Extending the benefits
Jasmohan S. Bajaj, Daniel M. Forton – 20 May 2013
Lipocalin‐2 negatively modulates the epithelial‐to‐mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF‐beta1)/Lcn2/Twist1 pathway
Yun‐Peng Wang, Goung‐Ran Yu, Mi‐Jin Lee, Sang‐Yeop Lee, In‐Sun Chu, Sun‐Hee Leem, Dae‐Ghon Kim – 20 May 2013 – Lipocalin‐2 (Lcn2) is preferentially expressed in hepatocellular carcinoma (HCC). However, the functional role of Lcn2 in HCC progression is still poorly understood, particularly with respect to its involvement in invasion and metastasis. The purpose of this study was to investigate whether Lcn2 is associated with the epithelial‐mesenchymal transition (EMT) in HCC and to elucidate the underlying signaling pathway(s).
Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome
Joseph E. Khabbaza, Richard A. Krasuski, Adriano R. Tonelli – 20 May 2013
Reply
Jerzy W. Kupiec‐Weglinski, Naoko Kamo – 20 May 2013
Cognitive improvement after HCV eradication: Extending the benefits
Jasmohan S. Bajaj, Daniel M. Forton – 20 May 2013
The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice
Noémie Péan, Isabelle Doignon, Isabelle Garcin, Aurore Besnard, Boris Julien, Bingkaï Liu, Sophie Branchereau, Anne Spraul, Catherine Guettier, Lydie Humbert, Kristina Schoonjans, Dominique Rainteau, Thierry Tordjmann – 17 May 2013 – Many regulatory pathways are involved in liver regeneration after partial hepatectomy (PH) to initiate growth, protect liver cells, and sustain functions of the remnant liver.
Invariant NKT cell activation induces neutrophil accumulation and hepatitis: Opposite regulation by IL‐4 and IFN‐γ
Hua Wang, Dechun Feng, Ogyi Park, Shi Yin, Bin Gao – 17 May 2013 – Alpha‐Galactosylceramide (α‐Galcer), a specific agonist for invariant natural killer T (iNKT) cells, is being evaluated in clinical trials for the treatment of viral hepatitis and liver cancer. However, the results from α‐Galcer treatment are mixed, partially because of the variety of cytokines produced by activated iNKT cells that have an unknown synergistic effect on the progression of liver disease.
Adipose tissue‐derived stem cells as a regenerative therapy for a mouse steatohepatitis‐induced cirrhosis model
Akihiro Seki, Yoshio Sakai, Takuya Komura, Alessandro Nasti, Keiko Yoshida, Mami Higashimoto, Masao Honda, Soichiro Usui, Masayuki Takamura, Toshinari Takamura, Takahiro Ochiya, Kengo Furuichi, Takashi Wada, Shuichi Kaneko – 17 May 2013 – Cirrhosis is a chronic liver disease that impairs hepatic function and causes advanced fibrosis. Mesenchymal stem cells have gained recent popularity as a regenerative therapy since they possess immunomodulatory functions. We found that injected adipose tissue‐derived stem cells (ADSCs) reside in the liver.